West Pharma posts beat-and-raise quarter aided by strong demand for injectables [Reuters]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Reuters
forecast, banking on rising demand for cartridges and syringes used to manufacture injectable therapies. The Pennsylvania-based company now expects 2024 profit in the range of $7.63 to $7.88 per share, compared with its previous forecast of $7.50 to $7.75 per share. Analysts had expected $7.62-per-share profit for 2024. The company expects sales growth to ramp up as the year progresses, partly due to a surge in demand for components used in the packaging of newer treatments, including Novo Nordisk's diabetes drug Ozempic, weight-loss drug Wegovy, and Eli Lilly's diabetes drug Mounjaro. West reiterated its full-year revenue outlook of $3 billion to $3.025 billion. CEO Eric Green said that he expects a majority of sales growth to take place in the second half, as biotech clients work through their existing inventory. "We are actively managing the timing of inventory decisions by some of our customers.." said Green. On an adjusted basis, the company posted a first-quarter pro
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Why Amgen Stock Zoomed Nearly 12% Higher Today [Yahoo! Finance]Yahoo! Finance
- Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market [Yahoo! Finance Canada]Yahoo! Finance Canada
- Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market [Yahoo! Finance]Yahoo! Finance
- The two ways Amgen's new weight-loss drug can stand out [Yahoo! Finance]Yahoo! Finance
- The two ways Amgen's new weight-loss drug can stand out [Yahoo! Finance Canada]Yahoo! Finance Canada
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 5/2/24 - Form 6-K
- 5/1/24 - Form 6-K
- 4/26/24 - Form 6-K
- NVO's page on the SEC website